Biological sex and gender have a tremendous impact on the efficacy and safety of pharmacological interventions in virtually every disease state. This book presents a comprehensive and up-to-date overview on how sex-specific information is guiding the diagnosis and treatment of diseases affecting men and women, as well as of disease states that disproportionally affects women. Experts in various fields discuss both preclinical and clinical research that is contributing to a better understanding of the impact of sex in the presentation, etiology, treatment, and disease outcomes. Also discussed are the challenges encountered in implementing this growing body of knowledge into practice, as well as possible avenues to recognize and reduce health disparities between men and women so that therapeutic interventions are tailored and improved.

Enriches awareness of varied responses to pharmacological interventions based on sex and gender Highlights clinical significance of biological sex or gender Summarizes the latest studies on knowledge gaps in women's health

Inhalt

Part 1 Pharmacological Basic Principles ** .- The impact of sex and gender in medicine and pharmacology.- Sex differences in pharmacokinetics.- Clinical pharmacological considerations in transgender medicine .- Sex and gender differences in the pharmacology of the overactive urinary bladder .- Part 2 Pathologies of the Brain.- Sex differences in the evaluation and treatment of stroke.- Sex differences in pain and its treatment.- Therapeutics For Substance-Using Women: The Need To Elucidate Sex-Specific Targets For Better-Tailored Treatments.- Intersection of sex and depression: pathogenesis, presentation and treatments.- Biological and clinical implications of sex-specific differences in Alzheimer's disease.- Part 3 Diabetes, metabolic diseases & cardiovascular risk.- Gender Differences In Cardiovascular Health: Hormonal Effects on Cardiovscular Risk And Management . - Sex Differences in Glucose Homeostasis.- Sex-gender-based differences in metabolic diseases.- Hypothalamic pituitary gonadal axis disorders impacting fertility in both sexes and the potential of kisspeptin-based therapies to treat them .